Next Article in Journal
Conditional Survival in Canada: Adjusting Patient Prognosis over Time
Previous Article in Journal
Psychosocial Care for Cancer: A Framework to Guide Practice, and Actionable Recommendations for Ontario
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Liver Transplantation for Symptomatic Liver Metastases of Neuroendocrine Tumours

1
Hôpital Maisonneuve–Rosemont, l’Université de Montréal, Montreal, QC, Canada
2
London Regional Cancer Program, University of Western Ontario, London, ON, Canada
3
Multi-Organ Transplant Program, University of Western Ontario, London, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2012, 19(4), 217-221; https://doi.org/10.3747/co.19.950
Submission received: 3 May 2012 / Revised: 5 June 2012 / Accepted: 8 July 2012 / Published: 1 August 2012

Abstract

Numerous reports have demonstrated that liver transplantation for neuroendocrine tumour metastasis is feasible. However, perioperative risks and long-term recurrences remain significant concerns. When liver transplantation is combined with extensive intestinal or pancreatic resection, the risk is particularly high. We report our institutional experience of liver transplantations performed for liver metastases secondary to neuroendocrine tumours, and in combination with a review of the literature, we propose a set of selection criteria. The key points include unresectable hepatic metastases of neuroendocrine origin, absence of extrahepatic metastases, symptomatic disease that is refractory to medical therapy, a Ki-67 level less than 2%, previous resection of the primary disease, and previous therapy for metastatic neuroendocrine tumour. In our experience, the patient in the first case had, post-transplantation, rapid disease progression because of an unidentified primary, and patient in the second case had primary non-function of the liver graft, requiring urgent re-transplantation. More recently, two liver transplantations were successfully performed. The indications were, in the first case, refractory hormonal secretion and, in the other, secondary biliary cirrhosis attributable to hepatic artery therapy with tumour in situ. Subclinical and stable recurrent disease has been detected by scintigraphy in the mesentery and lumbar spine in the former patient. A mesenteric recurrence developed in the latter patient 2 years post transplantation and was subsequently completely resected. At 4 and 5 years post transplantation, both patients are symptom-free. Recurrence after transplantation remains a significant concern, even with careful patient selection, but recurrences may remain indolent. If recurrences are progressive, they may still be amenable to additional medical or surgical therapy. A national or international consensus between oncologists and transplant specialists regarding the indications for liver transplantation is vital, because future progress will depend on careful patient selection and prospective study.
Keywords: liver transplantation; neuroendocrine tumour; liver metastases liver transplantation; neuroendocrine tumour; liver metastases

Share and Cite

MDPI and ACS Style

Chan, G.; Kocha, W.; Reid, R.; Taqi, A.; Wall, W.; Quan, D. Liver Transplantation for Symptomatic Liver Metastases of Neuroendocrine Tumours. Curr. Oncol. 2012, 19, 217-221. https://doi.org/10.3747/co.19.950

AMA Style

Chan G, Kocha W, Reid R, Taqi A, Wall W, Quan D. Liver Transplantation for Symptomatic Liver Metastases of Neuroendocrine Tumours. Current Oncology. 2012; 19(4):217-221. https://doi.org/10.3747/co.19.950

Chicago/Turabian Style

Chan, G., W. Kocha, R. Reid, A. Taqi, W. Wall, and D. Quan. 2012. "Liver Transplantation for Symptomatic Liver Metastases of Neuroendocrine Tumours" Current Oncology 19, no. 4: 217-221. https://doi.org/10.3747/co.19.950

Article Metrics

Back to TopTop